.png)
.png)
.png)
.png)
Since 2018, ArcaScience is providing advanced artificial intelligent models bringing original patient-centric information to help clinicians and safety specialists to deliver better drugs at scale.
Today, we deliver critical insights and studies out of the first comprehensive Patient Centric database in the world.
Discover now our tailored studies to de-risk, build & maintain more efficient treatments !
AI-assisted benefit-risk prediction - What if one could diferenciate the most promising drugs from the others, before reaching clinical trials? In 2023, it was made possible and had a critical impact multiple-sclerosis patients.
Read moreFor benefit-risk management
Safety Monitoring Report- Safety issues can go unnoticed buried in a sea of data, jeopardizing patient safety. What if you can monitor everything?
Read moreFor safety specialists
.jpg)
AI-assisted endpoint discovery- Feeling overwhelmed by the "COA Maze"? Clinical endpoints or Clinical Outcome Assessments (COAs) are essential for any clinical trial, but choosing the wrong one can derail an entire project.
Read moreFor clinical trial leaders
AI-assisted KOL identification - Recruitments are not enough targeted, resulting in severely delayed clinical trials. What if AI had proven its efficiency at bringing the most critical trials at the doorstep of these patients?
Read moreFor clinical trial leaders
.jpg)
1 location, 1 search engine, all your data for a simplified and improved literature review
Read moreFor literature review
%20(1).png)
Integrate any data into your eCRF and discover instantly how to handle your real-world studies
Read moreFor clinical operations
per drug
Adverse events mentions
Patient profiles
Bibliography
Over the last month
Weekly update available
per pathology
.svg)
Top endpoint (COAs)
Top PROMs, PerfOs & ClinROs
Top endpoint per drugs
Composite outcomes
Comprehensive CSV with endpoints since 1960
per pathology
HCPs KOL
Insitutional affiliations
Institutional collaborations
Similar populations investigated
Top and surging KOLs
per target
Safety issues
Biomarker mentions
Population screening
Drug mentions
Target mentions
On-demand
Risk analysis
Efficacy analysis
Benefit-risk value tree modelling
Comprehensive data integration
Competitor's drug benefit-risk value tree
.png)
.png)
.png)
.png)
A single endpoint report to discover the most promising COAs, PROms, ClinROs on a single pathology
Elevate your drug development process with the Benefit-Risk Prediction study by ArcaScience. This study provides critical insights to predict the benefit-risk profile of drugs at the earliest stages, allowing for informed decision-making and de-risking clinical trials.
Our KOL study delivers readily accessible, accurate, and secured recruitment sites data and exclusive analytics directly linked to your specific trial's pathology and targeted patient population.
A.S SafetyShield report, empower drug safety specialists with superior AI-driven insights for informed signal detection
Trusted by 8 biopharmas (Sanofi, Pfizer,.)
Robust scientific committee (INRIA, Roche,.)
10+ global academic partners (Sorbonne, ICM, AP-HP,.)
%20(1).jpg)
.png)
.png)
